EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells

Mihaela P Ficu, Dan Niculescu-Duvaz, Mohammed Aljarah, Christopher S Kershaw, Caroline J Springer iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202500133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Mihaela P Ficu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, SK10 4TG, UK. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Cell Cycle Proteins, Transcription Factors, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phenotypic effect induced by a Proteolysis‐Targeting Chimera (PROTAC) can depend on several factors, including the E3 ligase recruited. For the discovery of a first‐in‐class PROTAC for a target of interest, the E3 ligases commonly hijacked remain the Von Hippel‐Lindau (VHL) and Cereblon (CRBN) since potent and accessible ligands are readily available to recruit them. Mouse double minute 2 (MDM2) E3 ligase stands out because it regulates p53 levels to maintain cellular homeostasis. However, the synthesis of the most potent MDM2 ligands remains very complex. Herein, the discovery of novel MDM2‐recruiting PROTACs incorporating rac ‐Nutlin‐3 as a ligand with an easier synthetic tractability is reported, further demonstrating its potential in this technology. The most promising degrader, PROTAC 3 , showed preferential degradation of the BRD4 short isoform (BRD4 S) and c‐Myc compared with MZ1, a validated VHL‐based PROTAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Cell Cycle ProteinsTranscription FactorsPancreatic NeoplasmsUbiquitin-Protein LigasesHumansProteolysisCell Line, TumorPiperazinesImidazolesVon Hippel-Lindau Tumor Suppressor ProteinLigandsBromodomain Containing Proteins

Stichwörter der Autor:innen

BRD4HDM2MDM2MIA PaCa‐2PROTACspancreatic cancertargeted protein degradation

Substanzen

Proto-Oncogene Proteins c-mdm2Cell Cycle ProteinsTranscription FactorsBRD4 protein, humanMDM2 protein, humanUbiquitin-Protein LigasesPiperazinesnutlin 3ImidazolesVon Hippel-Lindau Tumor Suppressor Protein

Autor:innen und Institutionen

  • Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, SK10 4TG, UK.
  • Oncodrug Ltd, Alderley Park, Macclesfield, SK10 4TG, UK.

ORCID-Profile: Caroline J Springer

Förderung

  • Cancer Research UK

Zitieren

APA

Ficu, M. P., Niculescu-Duvaz, D., Aljarah, M., Kershaw, C. S., & Springer, C. J. (2025). Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells. ChemBioChem. https://doi.org/10.1002/cbic.202500133

Vancouver

Ficu MP, Niculescu-Duvaz D, Aljarah M, Kershaw CS, Springer CJ. Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells. ChemBioChem. 2025. doi:10.1002/cbic.202500133

BibTeX
@article{Ficu2025,
  author = {Ficu, Mihaela P and Niculescu-Duvaz, Dan and Aljarah, Mohammed and Kershaw, Christopher S and Springer, Caroline J},
  title = {Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202500133}
}
Kostenlos starten →